GC Pharma marks World Hemophilia Day


As part of its ongoing support for the hemophilia community, GC Pharma is presenting the image of this year's slogan on its global site and the gigantic outer fa├žade of its main campus in Yongin, South Korea.

"GC Pharma is proud to support the global hemophilia community by marking World Hemophilia Day," said Dr. EC Huh, President of GC Pharma. "We will also work to develop innovative medicines to improve the quality of life of people with bleeding disorders."

World Hemophilia Day (WYD) is held annually on April 17 and, since its inception in 1989, is an opportunity to raise public awareness about hemophilia and other hemorrhagic disorders.

About hemophilia

Hemophilia is a congenital disorder that causes bleeding for longer than normal due to the absence or deficiency of the blood clotting factor. Hemophilia A, more common than hemophilia B, affects approximately 30,000 people and affects approximately 150,000 people worldwide. Therapeutic diets typically consist of prophylactic and / or regular on-demand replacement factor infusions on demand to control or prevent the risk of bleeding. People with hemophilia, who work closely with their healthcare teams, can lead a healthy life through proper care and proper treatment.

About GC Pharma

GC Pharma (formerly Green Cross Corporation) is a biopharmaceutical company that provides life-saving therapeutic products and vaccine vaccines. Headquartered in South Korea, GC Pharma, which has been dedicated to quality healthcare solutions for more than half a century, is the largest manufacturer of plasma proteins in Asia. Green Cross Corporation, although it became GC Pharma, after updating its corporate brand in early 2018, remains the company's registered name.

Photo – https://mma.prnewswire.com/media/872360/GC_Pharma_Hemophilia.jpg


For more information: MEDIA CONTACT: Woo Sub Shin, Director of Public Relations, GC (Green Cross Holdings), [email protected], +; Ji Woong Kim, Director of Public Relations, GC (Green Cross Holdings), [email protected], +


Source link